Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Commercial Insight: Antibacterials' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Commercial Insight: Antibacterials Growth in resistance rates drives niche indications |
December 2006 | £8000 | 100 % |
|
Commercial Insight Antibacterials Growth in resistance rates drives niche indications |
January 2007 | £8000 | 100 % |
|
Commercial & Pipeline Insight: Hospital Antibacterials A market beyond MRSA |
August 2007 | £8010 | 95 % |
|
Infectious Diseases Overview Commercial Insight |
December 2007 | £7600 | 70 % |
|
Autoimmune Overview - Market Continues To Prosper Commercial Insight |
December 2007 | £7600 | 70 % |
|
Urinary Incontinence - Lifecycle Management Strategies Retain Mid-Term Market Growth Pipeline And Commercial Insight |
December 2007 | £7600 | 68.6 % |
|
Commercial Insight: Depression Atypical lifecycle management strategy rejuvenates depression market |
June 2007 | £7600 | 56 % |
|
Commercial Insight: Epilepsy Companies Committed To The Cause Will Reap The Benefits |
September 2007 | £7600 | 56 % |
|
Commercial Insight: Antidyslipidemics Branded statins beware, generics are amongst you |
July 2006 | £8440 | 56 % |
|
Commercial Insight: Antihypertensives New challenges for a maturing market |
September 2006 | £8000 | 56 % |
|
Commercial Insight: Osteoporosis Risk management and reformulation offer best defense against generic onslaught |
June 2007 | £7600 | 56 % |
|
Pipeline And Commercial Insight Pediatric And Adolescent Vaccines |
July 2007 | £8000 | 56 % |
|
Commercial Insight: Antithrombotics Market expands as disease management focuses on prevention |
October 2007 | £7600 | 56 % |
|
Commercial Insight: Antidyslipidemics The competitive cost-conscious antidyslipidemics market presents challenges |
July 2007 | £7600 | 56 % |
|
Commercial and Pipeline Insight Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead |
July 2008 | £7700 | 56 % |
|
Commercial and Pipeline Insight Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead |
July 2008 | £7700 | 56 % |
|
Commercial Insight: Migraine Opportunities Will Exist In The Wake Of Generic Attack |
September 2007 | £7600 | 56 % |
|
Commercial Insight Antithrombotics Pipeline products to dampen the impact of patent expiries and cost containment initiatives |
February 2007 | £8000 | 56 % |
|
Commercial Insight: Osteoarthritis Market sees steady growth |
December 2006 | £8000 | 56 % |
|
Commercial Insight: Transplantation |
June 2006 | £8695 | 56 % |
|
Commercial and Pipeline Insight: Psoriasis Anti-TNF's lead another indication |
December 2006 | £8000 | 55 % |
|
Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment |
June 2007 | £7600 | 55 % |
|
Commercial Insight: Pain Market Overview Non-Traditional Analgesics and Opioid Reformulations to Sustain Sector Growth |
October 2008 | £8000 | 55 % |
|
Pipeline and Commercial Insight: Alzheimer's Disease Scenario Forecasts Reveal Vast Market Potential |
March 2008 | £7600 | 55 % |
|
Commercial Insight: CNS Market Overview Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors |
April 2008 | £8000 | 55 % |
|
Commercial and Pipeline Insight: ADHD Immature adult market continues to offer greatest commercial potential |
April 2008 | £8000 | 55 % |
|
Commercial and Pipeline Insight: Opioids Short Acting and Anti-Abuse Technologies Set to Fragment and Grow The Market |
March 2008 | £7600 | 55 % |
|
Pipeline And Commercial Insight: Parkinson's Disease Market To Grow As First Round Of Lifecycle Management Strategies Succeed |
September 2007 | £7600 | 55 % |
|
Colorectal Cancer: Pipeline/Commercial Insight Shaping the future dynamics of colorectal cancer management |
October 2006 | £8000 | 55 % |
|
Commercial Insight: Cardiovascular market overview Raft of patent expires threaten blockbusters |
October 2007 | £7600 | 55 % |
|
Commercial and Pipeline Insight: Hepatitis B |
October 2007 | £7600 | 55 % |
|
Commercial and Pipeline Insight: Systemic antifungals |
November 2007 | £7600 | 55 % |
|
Commercial Insight: Asthma & COPD Combination Products Still Have Blockbuster Potential |
July 2007 | £7600 | 55 % |
|
Commercial Insight: Neuropathic Pain A Plethora of Patient Segmentation and Product Differentiation Opportunities |
July 2006 | £8440 | 55 % |
|
Commercial Insight Top 20 Cancer Therapeutics |
July 2006 | £8695 | 55 % |
|
Pipeline/Commercial Insight: Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications |
June 2007 | £7600 | 54 % |
|
Commercial and Pipeline Insight: HRT for Menopausal Symptoms A new class restores an old market |
April 2008 | £8000 | 54 % |
|
Commercial Insight: Top 20 Cancer Therapy Brands Sales of targeted therapies overtake cytotoxics in 2006 |
July 2007 | £7600 | 54 % |
|
Commercial Insight: Antihormonal Therapy Cancer Brands Careful Lifecycle Management Needed to Preserve Brand Dominance |
August 2008 | £7600 | 54 % |
|
Commercial Insight: Cytotoxic Therapy Cancer Brands Looming Patent Expiries Limit Market Growth |
July 2008 | £7600 | 54 % |
|
Commercial Insight: Cardiovascular and metabolic market overview Diabetes to the fore as generics hit primary care markets |
February 2009 | £8000 | 54 % |
|
Commercial and Pipeline Insight: Inflammatory Bowel Disease Competition Increases for the Biologics |
November 2006 | £6000 | 54 % |
|
Commercial Insight: Targeted Therapy Cancer Brands High Growth Market Will See Eight New Blockbusters by 2017 |
July 2008 | £7600 | 54 % |
|
Commercial Insight: HIV - The battle for market share is getting fiercer |
August 2008 | £7600 | 53 % |
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline |
October 2006 | £8000 | 53 % |
|
Pipeline and Commercial Insight: Schizophrenia - Second generation depots protect market value |
October 2008 | £8000 | 53 % |
|
Commercial Insight: Select Herpes Viruses and Human Papilloma Virus Non-Biologic Interventions for Oral and Genital Herpes, Cytomegalovirus Infection, Herpes Zoster and Genital Warts |
August 2008 | £7600 | 53 % |
|
Pipeline and Commercial Insight: Nicotine Dependence - Chantix issues overshadow vaccine potential Healthcare |
March 2009 | £8000 | 52 % |
|
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries |
July 2007 | £7600 | 52 % |
|
Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies |
November 2008 | £8000 | 52 % |
|
Forecast Insight: Opioids - Saturation limits the commercial potential of individual brands Healthcare |
March 2009 | £8000 | 52 % |
|
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products |
August 2007 | £8010 | 51 % |
|
Stakeholder Opinions Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies |
July 2008 | £3800 | 24 % |
|
Stakeholder Opinions: Cystic Fibrosis |
March 2006 | £2195 | 23.5 % |
|
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market? - Cancer |
October 2007 | £7600 | 20 % |
|
Pipeline Insight: Molecular Targeted Cancer Therapies More pipeline activity, less product differentiation |
November 2008 | £8000 | 19 % |
|
Stakeholder Opinions: Sepsis The Critical Care Community Gains Critical Mass |
March 2008 | £2050 | 19 % |
|
Monoclonal Antibodies Report Market Model |
June 2007 | £3800 | 18 % |
|
Stakeholder Opinions: Fibromyalgia Potentially lucrative market soon to become reality |
May 2007 | £2005 | 18 % |
|
Pipeline Insight: Bipolar Disorder New treatments for bipolar depression set to drive near-term growth |
September 2006 | £6495 | 17.5 % |
|
Healthcare and Pharmaceuticals in Latin America A guide to the markets and regulations |
May 2005 | £525 | 17.5 % |
|
Pipeline Insight: Neuropathic Pain Emerging Drugs Fail To Capitalize In Lucrative Market |
September 2007 | £740 | 17 % |
|
Stakeholder Opinions: Bladder Cancer New drugs needed to challenge ineffective 20 year old drugs |
November 2008 | £2000 | 16.5 % |
|
Teleflex Incorporated - Financial and Strategic Analysis Review |
June 2009 | £76 | 16.5 % |
|
Substance Dependence - Part II: Alcohol Pipeline Insight |
December 2007 | £3800 | 15.4 % |
|
Pipeline Insight: Epilepsy Pipeline drugs struggle to outshine their marketed predecessors |
October 2006 | £6000 | 15 % |
|
Stakeholder Opinions: Melanoma Lucrative commercial opportunities persist |
December 2006 | £2005 | 15 % |
|
Generics Series Key Trends And Events In The 7 Major Markets |
December 2007 | £2005 | 14.7 % |
|
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects |
August 2008 | £1495 | 14.5 % |
|
Pipeline Insight: Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
December 2006 | £6000 | 14.5 % |
|
Monoclonal Antibodies Report Part I |
June 2007 | £3800 | 14 % |
|
Pipeline Insight: Cancer Overview Increasing Diversity Offers Both High Risk And Reward |
September 2007 | £7600 | 14 % |
|
Epigenetics Technologies, Applications, and the Commercial Landscape |
February 2008 | £685 | 13.65 % |
|
Stakeholder Opinions: Respiratory Syncytial Virus (RSV) A market yet to reach its full potential |
December 2006 | £2005 | 13.5 % |
|
Preclinical Cancer Therapeutics 2007 Decoding Next Generation Drug Targets for Market Success |
December 2006 | £1600 | 13.5 % |
|
Monoclonal Antibodies Report |
June 2008 | £3800 | 13.5 % |
|
Stakeholder Opinions Respiratory Syncytial Virus (RSV) A market yet to reach its full potential |
January 2007 | £2005 | 13.5 % |
|
PDL BioPharma, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 13 % |
|
Vasogen Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 13 % |
|
Arrow International, Inc. - Strategic Analysis Review |
June 2009 | £76 | 13 % |
|
Cougar Biotechnology, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 13 % |
|
Covance Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 13 % |
|
Stakeholder Opinions: Biologics in Infectious Diseases Well Defined Target Populations Are Key to Commercial Success |
March 2008 | £2005 | 12.95 % |
|
Vical Incorporated - Financial and Strategic Analysis Review |
April 2009 | £76 | 12.5 % |
|
Molecular Imaging in Drug R&D and Medical Practice Technologies, Applications, Markets |
January 2008 | £685 | 12.5 % |
|
SeraCare Life Sciences, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 12.5 % |
|
QLT Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 12.5 % |
|
The OTC Animal Health Global Market Opportunity |
January 2007 | £895 | 12.5 % |
|
Indian Pharmaceuticals Industry Report |
October 2007 | £400 | 12.25 % |
|
Perot Systems Corporation - Financial and Strategic Analysis Review |
June 2009 | £76 | 12 % |
|
OraSure Technologies, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 12 % |
|
Moog Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 12 % |
|
Exact Sciences Corporation - Financial and Strategic Analysis Review |
June 2009 | £76 | 12 % |
|
Acorda Therapeutics, Inc. - Financial and Strategic Analysis Review |
June 2009 | £76 | 12 % |
|
TietoEnator Corporation - Financial and Strategic Analysis Review |
June 2009 | £76 | 12 % |
|
Rx-to-OTC Strategies Maximizing The Commercial Potential of An Rx-to-OTC Switch |
June 2008 | £2995 | 12 % |
|
Leukemia - A Therapeutic & Competitive Insight |
October 2006 | £1670 | 12 % |
|
SkyePharma PLC - Financial and Strategic Analysis Review |
April 2009 | £76 | 12 % |
|
Multiple Myeloma - Exploring New Targets For Multiple Drug Therapy Stakeholder Opinions |
December 2007 | £2005 | 11.55 % |
|
Systems Biology A Disruptive Technology |
May 2008 | £685 | 11.55 % |
|
The Antipsychotics Market Insight & Analysis 2008 |
February 2008 | £1499 | 11.5 % |
|
Coventry Health Care, Inc. - Financial and Strategic Analysis Review |
April 2009 | £76 | 11.5 % |
|
Antipsychotics Market Insight & Analysis 2008 |
February 2008 | £1499 | 11.5 % |
|
Reformulation Strategies Comparisons of Past and Future Reformulation Strategies |
September 2006 | £4000 | 11 % |
|
eCME: Leveraging Online Continuing Medical Education as a Channel of Influence |
July 2006 | £2230 | 11 % |
|
World Diabetes Market Analysis 2009-2023 |
February 2009 | £1499 | 11 % |
|
Stakeholder Opinions: Head and Neck Cancer Innovatives to Change the Face of Treatment |
November 2007 | £2005 | 11 % |
|
Cancer Biomarkers: Adoption Is Driving Growth |
July 2008 | £2290 | 10.85 % |
|
Pipeline Insight: Depression Novel drugs to grow third-line market |
March 2007 | £6000 | 10.5 % |
|
Stakeholder Opinions: Bone Metastases Impending Patent Expiries May Help Make or Break Newer Agents |
March 2008 | £2005 | 10.5 % |
|
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies |
May 2006 | £2960 | 10.5 % |
|
Breast Cancer - Therapeutic And Competitive Insights |
February 2007 | £1340 | 10.5 % |
|
Breast Cancer Therapeutic And Competitive Insights |
February 2007 | £1340 | 10.5 % |
|
In Vitro Diagnostics Market Report & Analysis 2008-2023 |
June 2008 | £1499 | 10 % |
|
Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
February 2007 | £1495 | 10 % |
|
Innovative And Targeted Cancer Therapies Key Technologies, New Applications And Leading Players |
July 2007 | £1495 | 10 % |
|
Stakeholder Opinions: Osteoarthritis Preconceptions Damage Awareness and Treatments |
March 2006 | £2195 | 10 % |
|
Bioinformatics Report The forecasts and future of the market 2006-2011 |
October 2006 | £1499 | 10 % |
|
Prostate and Breast Cancer New Treatments & Developmental Progress |
March 2007 | £2025 | 10 % |
|
Stakeholder Perspectives: Pulmonary Arterial Hypertension A small market gets big attention |
February 2006 | £4350 | 10 % |
|
World Market for Addiction Disorders 2005-2012, The New Horizons in High-Profile Dependency Markets |
December 2005 | £1100 | 10 % |
|
Cymbalta Case Study Successfully Entering a Crowded Market with a New Mechanism of Action |
June 2008 | £3170 | 9.8 % |
|
Pipeline Insight: Insulins Inhalable insulins unlikely to become blockbusters |
September 2006 | £6000 | 9.8 % |
|
Pipeline Insight: Orphan Diseases in Neurology Part III: Myasthenia Gravis |
November 2008 | £6000 | 9.8 % |
|
Pharmaceutical Strategic Alliances Maximizing returns from collaborative development and commercialization |
September 2006 | £1495 | 9.5 % |
|
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome Reformulations set to drive near-term growth |
August 2006 | £8695 | 9.5 % |
|
Pipeline Insight: Nosocomial Vaccines Minefield or Goldmine? |
April 2008 | £6000 | 9.45 % |
|
Pipeline Insight: Schizophrenia |
July 2006 | £6330 | 9.1 % |
|
Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos Healthcare |
March 2009 | £2000 | 9.1 % |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas |
June 2007 | £2365 | 9 % |
|
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntington's Disease |
November 2007 | £3800 | 8.75 % |
|
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents |
October 2006 | £2960 | 8.5 % |
|
Leading Drug Delivery Companies and Technologies Competitive landscape, company profiles and technological developments |
June 2008 | £1995 | 8.5 % |
|
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer |
March 2006 | £2960 | 8.5 % |
|
Stakeholder Opinions: Diabetic Renal Disease |
November 2008 | £2000 | 8.4 % |
|
Stakeholder Insight: Metabolic Syndrome Multiple definitions complicate treatment |
April 2006 | £8690 | 8.4 % |
|
Stakeholder Opinions: Systemic Lupus Erythematosus Market Set to Enter Era of Biologic Therapies |
March 2008 | £2050 | 8.4 % |
|
Stakeholder Opinions: Back Pain Gain competitive edge by targeting subpopulations |
March 2009 | £2000 | 8.05 % |
|
Pipeline Insight: Breast Cancer Recent approvals increase pressure on pipeline candidates |
April 2008 | £6000 | 8.05 % |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer |
June 2007 | £2365 | 8 % |
|
Current and Future Therapies for Lung Cancer A Therapeutic & Competitive Insight |
March 2006 | £1670 | 8 % |
|
Lymphoma A Therapeutic & Competitive Insight |
May 2006 | £1670 | 8 % |
|
Next Generation Protein Engineering and Drug Design Strategies to boost efficacy and improve drug delivery |
February 2007 | £1495 | 8 % |
|
Discovery Stage Partnering Agreements in Biopharma |
September 2008 | £1195 | 8 % |
|
Targeted Therapeutics in Non-Small Cell Lung Cancer |
April 2007 | £1340 | 8 % |
|
The Licensing Agreement in Pharmaceutical Business Development 3rd edition |
July 2007 | £450 | 7.5 % |
|
Hematological Cancers - A Therapeutic & Competitive Insight |
October 2006 | £2530 | 7.5 % |
|
Licensing Agreement in Pharmaceutical Business Development, The 3rd Edition |
July 2007 | £700 | 7.5 % |
|
Pre-clinical Stage Partnering Agreements in Biopharma |
October 2008 | £1195 | 7.5 % |
|
Drug Delivery Technologies: Players, products & prospects to 2015 |
November 2007 | £1795 | 7.5 % |
|
Major Pharmaceutical Markets of the Middle East An overview of Egypt, Israel, Jordan, Lebanon, Saudi Arabia & UAE (2nd Ed) |
February 2009 | £1295 | 7 % |
|
Marketing ROI for Pharma |
January 2006 | £75 | 7 % |
|
Drug Safety for Marketed Drugs |
April 2006 | £75 | 7 % |
|
Market for SNP Genotyping Products & Services; The |
July 2005 | £2195 | 7 % |
|
Cardiotoxicity: Issues, Technologies, and Solutions for the Future |
May 2008 | £2290 | 6.65 % |
|
Pipeline Insight: Anxiety Disorders A decade of declining revenues |
March 2006 | £6495 | 6.65 % |
|
Pipeline Insight: Acute Stroke Commercial Risk Offsets High Unmet Need |
May 2008 | £6000 | 6.65 % |
|
Online Marketing and eDetailing Europe |
July 2007 | £75 | 6.65 % |
|
Pipeline Insight: Non-insulin Antidiabetics Type 2 diabetes unlikely to develop into a switch market |
August 2006 | £6495 | 6.65 % |
|
MicroRNAs Commercial Products on the Horizon |
March 2008 | £685 | 6.65 % |
|
Stakeholder Insight: Atherosclerosis HDL, ApoA-I, Carotid MRI and 64-slice CT offer opportunities for future treatment |
December 2006 | £8000 | 6.3 % |
|
Pipeline Insight: Therapeutic Cancer Vaccines A turbulent path from bench to bedside |
December 2006 | £6000 | 6.3 % |
|
Drug Testing: Technologies and Global Markets |
January 2008 | £2960 | 6 % |
|
Stakeholder Opinions: Primary Brain Cancer Temozolomide Turns Heads |
July 2007 | £2005 | 5.95 % |
|
Wyeth PharmaVitae Profile |
July 2008 | £3010 | 5.6 % |
|
Wyeth: PharmaVitae Profile PharmaVitae Profile |
March 2009 | £3010 | 5.6 % |
|
The Global HIV/Aids Market Outlook To 2012 |
July 2007 | £1495 | 5.5 % |
|
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The Challenge Of Turning Technology Into Therapy |
July 2007 | £1999 | 5.5 % |
|
Stakeholder Insight: Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines |
December 2006 | £8000 | 5.25 % |
|
Stakeholder Opinions: Acute Leukemias Persistent unmet needs confer significant commercial opportunity |
April 2006 | £2170 | 5.25 % |
|
Merck & Co. Inc: PharmaVitae Profile |
March 2009 | £3010 | 5.25 % |
|
Antiageing and Life Enhancement Pharmacotherapeutics |
January 2006 | £4600 | 5 % |
|
Multiplex Assays in Translational Medicine Technologies, Applications, and Future Directions |
February 2008 | £685 | 4.9 % |
|
Pipeline Insight: Breakthrough Pain Fast-acting players will capture majority market share |
November 2006 | £6000 | 4.9 % |
|
Stakeholder Opinions: Tuberculosis - Development pipeline shows signs of life Healthcare |
March 2009 | £2000 | 4.9 % |
|
Pipeline Insight: Hepatitis C Protease inhibitors to drive market expansion |
June 2006 | £6495 | 4.55 % |
|
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry |
April 2009 | £6000 | 4.55 % |
|
Terahertz Radiation Systems Technologies and Global Markets |
November 2008 | £1985 | 4.55 % |
|
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
November 2006 | £6000 | 4.2 % |
|
Regional Volume I: Europe The Guide to Distributors of Medical Equipment & Supplies Worldwide 2007 |
July 2007 | £195 | 3.85 % |
|
Regional Volume IV: Asia Pacfic The Guide to Distributors of Medical Equipment & Supplies Worldwide 2007 |
July 2007 | £195 | 3.85 % |
|
Stakeholder Opinions: Gynecological Cancers Niche opportunities in advanced disease |
December 2006 | £2005 | 3.85 % |
|
Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
April 2008 | £6000 | 3.5 % |
|
The Guide to Distributors of Medical Equipment & Supplies Worldwide 2009 |
March 2009 | £495 | 1.05 % |
